Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives

Transfusion

Volumn 46, Issue 7, 2006, Pages 1143-1151

  Kreil, Thomas R ^a,b   Wieser, Andreas ^a   Berting, Andreas ^a   Spruth, Martin ^a   Medek, Christian ^a   Pölsler, Gerhard ^a   Gaida, Theodor ^a   Hämmerle, Thomas ^a   Teschner, Wolfgang ^a   Schwarz, Hans Peter ^a   Barrett, P Noel ^a  

^a Global Pathogen Safety   (Austria)

^b BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ARTICLE; HEPATITIS A VIRUS; NANOFILTRATION; NONHUMAN; PARVOVIRUS; PLASMA; POLYMERASE CHAIN REACTION; VIRAL CONTAMINATION; VIRUS INFECTIVITY;

ANIMALS; ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY COMPLEX; FILTRATION; HEPATITIS A VIRUS, HUMAN; HUMANS; MICE; MINUTE VIRUS OF MICE; NANOSTRUCTURES; PARVOVIRUS B19, HUMAN; PLASMA; POROSITY; VIRUSES;

EID: 33746475142     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00864.x     Document Type: Article

References (26)

1. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA. Virus taxonomy: classification and nomenclature of viruses - Eighth report of the international committee on the taxonomy of viruses. San Diego: Elsevier/Academic Press; 2005.
2. Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002;118:1187-9.
3. Farrugia A. Risk of parvovirus infection by immuno globulin. Br J Haematol 2003;121:955-6.
4. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003;9:24-37.
5. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994;67:132-8.
6. Omar A, Kempf C. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion 2002;42:1005-10.
7. Cooper DK, Tseng YL, Saidman SL. Alloantibody and xenoantibody cross-reactivity in transplantation. Transplantation 2004;77:1-5.
8. Guideline on Assessing the Risk for Virus Transmission - New Chapter 6 of the Note for Guidance on Plasma Derived Medicinal Products (CPMP/BWP/269/95) [monograph on the Internet]. CPMP/BWP/5180/03. London: European Medicines Agency; 2004. Available from: http:// www.emea.eu.int/pdfs/human/bwp/518003en. pdf
9. Gruber F, Falkner FG, Dorner F, Hammerle T. Quantitation of viral DNA by real-time PCR applying duplex amplification, internal standardization, and two-color fluorescence detection. Appl Environ Microbiol 2001;67:2837-9.
10. Hammerle T, Himmelspach M, Dorner F, Falkner FG. A sensitive PCR assay system for the quantitation of viral genome equivalents: human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV). Arch Virol 1997;142: 1297-306.
11. Deutz A, Fuchs K, Schuller W, et al. [Seroepidemiological studies of zoonotic infections in hunters in southeastern Austria - prevalences, risk factors, and preventive methods]. Berl Munch Tierarztl Wochenschr 2003;116:306-11.
12. Blumel J, Schmidt I, Willkommen H, Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002;42:1011-8.
13. Yunoki M, Tsujikawa M, Urayama T, et al. Heat sensitivity of human parvovirus B19. Vox Sang 2003;84:164-9.
14. Caillet-Fauquet P, Draps ML, Di Giambattista M, de Launoit Y, Laub R. Hypoxia enables B19 erythrovirus to yield abundant infectious progeny in a pluripotent erythroid cell line. J Virol Meth 2004;121:145-53.
15. Caillet-Fauquet P, Di Giambattista M, Draps ML, et al. An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell lines. Transfusion 2004; 44:1340-3.
16. Yokoyama T, Murai K, Murozuka T, et al. Removal of small non-enveloped viruses by nanofiltration. Vox Sang 2004; 86:225-9.
17. Troccoli NM, McIver J, Losikoff A, Poiley J. Removal of viruses from human intravenous immune globulin by 35Nm nanofiltration. Biologicals 1998;26:321-9.
18. Allander T, Tammi MT, Eriksson M, et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005;102: 12891-6.
19. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997;72:1-10.
20. Dockrell DH, Poland GA, Jones MF, Smith TF. Variability in parvovirus B19 IgG levels in intravenous immunoglobulin samples. Diagn Microbiol Infect Dis 1996;26:133-5.
21. Blumel J, Schmidt I, Effenberger W, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002;42:1473-81.
22. Wu CG, Mason B, Jong J, et al. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005;45:1003-10.
23. Chudy M, Budek I, Keller-Stanislawski B, et al. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol 1999;57:91-9.
24. Eis-Hubinger AM, Sasowski U, Brackmann HH, et al. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products. Thromb Haemost 1996;76:1120.
25. Burnouf T, Radosevich M, El-Ekiaby M, et al. Nanofiltration of single plasma donations: feasibility study. Vox Sang 2003;84:111-9.
26. Barnett GR, Tannock GA, Paul JA, Bryce DA. An improved membrane-filtration enzyme immunoassay for the rapid serological diagnosis of viral infections. J Virol Meth 1988;20:323-32.